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B
ecause of its high prevalence and
potential to alter critical elements of
sepsis pathophysiology, diabetes is
likely an important comorbid condition
in this disease; yet the exact inﬂuence of
diabetes on infection and the develop-
mentofsepsisremainundeﬁned.Theaim
of this article is to review evidence from
preclinicalandclinicaltrialstodiscussthe
inﬂuence of diabetes on sepsis patho-
physiology, susceptibility, and clinical
outcomes.
Evidence from animal and in vitro
studies
Diabetes has reduced bacterial clear-
ance in animal models. As e r i e so f
studies investigated whether diabetic
miceresponded differently tosepsiscom-
pared with mice without diabetes.
Thereby, 1–2 weeks prior to the experi-
ment, diabetic conditions were induced
with streptozotocin,acytotoxicantibiotic
substance isolated from Streptomyces ach-
romogenes, which produces irreversible
damage to pancreatic b-cells resulting in
hyperglycemia. When mice were experi-
mentally infected with group B strepto-
coccal bacteria, diabetic mice had
reduced clearance of bacteria and higher
mortality rates (1). Remarkably, the in-
creased mortality in diabetic animals oc-
curred later in the course of the disease
(after 72 h) and was associated with per-
sistent bacteremia and prolonged seques-
tration of viable microorganisms in the
hepaticandsplenicreticuloendothelialsys-
tem. Similar ﬁndings were reported after
infecting diabetic mice with Pseudomonas
aeruginosa, where there was a direct asso-
ciation between increased numbers of mi-
croorganisms in liver, kidney, and spleen,
and mortality (2). A more recent study
investigated the host defense against tu-
berculosis (3). Diabetic mice had a sig-
niﬁcantly higher bacterial burden and
increased inﬂammation in the lung.
Production of g-interferon (IFN-g)w a s
reduced by the presence of fewer antigen–
responsiveT-cells.Interestingly,Yamashiro
et al. (4) expanded upon these ﬁndings by
demonstrating increased numbers of live
mycobacteria in lung, liver, and spleen,
and lower IFN-g and interleukin (IL)-12
cytokine levels in diabetic mice. Impor-
tantly, the control of blood glucose levels
by insulin therapy in this study resulted in
improvement of the impaired host protec-
tion and T helper type 1-related cytokine
synthesis.
Hyperglycemia impairs polymorpho-
nuclear neutrophil cell function and
cytokine production. Compelling evi-
dence that diabetes impairs host defense
is derived from in vitro studies demon-
strating that important functions of the
innate immunity are deﬁcient in diabetic
patients (Table 1). In vitro studies dem-
onstrate that polymorphonuclear neutro-
phil (PMN) cells—the cornerstone of
innate immunity—have impaired perfor-
mance in the presence of hyperglycemia
(5,6). In a series of experiments using
blood from diabetic patients, Delamaire
et al. (5) demonstrated a reduction of
PMN cell function, including reduced en-
dothelial adherence, chemotaxis, phago-
cytosis, and bacterial killing. Notably,
hyperglycemia was identiﬁed as the
main mechanism responsible for the al-
teration in immune function, while type
of diabetes, patient age, A1C level, and
disease duration were not found to affect
immunefunction.Anotherstudy(6)found
that hyperglycemia induces an increase in
intracellular calcium concentrations and
thereby reduces ATP (adenosine triphos-
phate) levels, which in turn leads to re-
duced phagocytic ability of PMN cells.
Correction of hyperglycemia led to a sig-
niﬁcant reduction in intracellular calcium
levels, an increase in ATP content, and im-
proved phagocytosis.
There is additional evidence that hy-
perglycemia interacts with different im-
mune and hemostatic responses during
experimental human endotoxemia (7,8).
Stegenga et al. (7) found reduced neutro-
phil degranulation and exaggerated coag-
ulation during human hyperglycemia,
with a reversal of these effects when glu-
cose was controlled with insulin therapy.
In another study by Stegenga et al. (8),
investigators found direct effects of hy-
perglycemia and insulin on gene expres-
sion during human endotoxemia.
Hyperglycemia led to decreased lipopoly-
saccharides-stimulated mRNA levels of
different proinﬂammatory cytokines (nu-
clear factor of k light polypeptide gene en-
hancer in B-cells inhibitor a [NFkBIa],
interleukin-1a [IL-1a], and chemokine
[C-C motif] ligand 3 [CCL3]) compared
with the euglycemic state, whereas insu-
lin therapy inﬂuenced the expression of
these inﬂammatory genes in the opposite
direction.
Hyperglycemia has been shown to
increase the duration of the cytokine
response. A study (9) investigated the cy-
tokine response to inoculation of bacteria
in hyperglycemic mice 14 days after
streptozotocintreatment.Theinitialcyto-
kine response was similar, but diabetic
mice showed a prolonged cytokine re-
sponse over 3–5 days. The results were
subsequently validated in a type 2 diabe-
tes mouse model (db/db), where a pro-
longed production of the inﬂammatory
cytokine tumor necrosis factor (TNF)-a
was found. Other research has found
that hyperglycemia may impair cytokine
production locally, apart from the
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REVIEWsystemic response. For example, diabetic
women with bacteriuria present lower
urinary levels of IL-6 and IL-8 (10). Pro-
duction of macrophage-speciﬁcp r o t e i n s
w a sa l s oi m p a i r e di na l v e o l a rm a c r o -
phages in diabetic mice challenged
with intratracheal lipopolysaccharides
(11).
Diabetes has direct effects on the
adaptive immune system. Inadditionto
PMN cell function and cytokine expres-
sion,diabeteshasadirectinhibitoryeffect
on the adaptive immune system. Spatz
et al. (12) demonstrated a decreased pro-
liferative response and delayed hypersen-
sitivity reaction of T-cell function in
diabetic patients. This was also true in an-
imal models of diabetes, especially when
the duration of diabetes was prolonged
(13). Dysfunction of T-cells within these
studies has been attributed to both a dis-
regulation between anti-inﬂammatory
and proinﬂa m m a t o r yc y t o k i n e sa sw e l l
as defects at the level of antigen-present-
ing cells (12,13). Diabetic mice display a
lower production of IgM and IgG anti-
bodies against a T-cell–dependent or –in-
dependent antigen (13). Additionally, a
directeffectofhighglucoseconcentration
on lymphoid cell growth leading to early
celldeath wasobserved. Diabetic patients
with poor long-term glucose control (ele-
vated A1C levels) were found to have
lower concentrations of circulating IgG
antibodies (14). Other researchers found
not only quantitative effects, but also
qualitative defects. Lower functionality
of IgG antibodies and impairment of an-
tigen binding as a result of direct nonen-
zymatic glycation were displayed in
diabetic patients (15). Still, an impact be-
causeoftheseantibodyalterationshasnot
yet been demonstrated, and diabetic pa-
tients seem to respond similarly to vacci-
nations compared with nondiabetic
patients (16).
Insulin may be protective to the host
response. The effect of insulin on the
host response may be explained by two
different mechanisms. First, insulin may
prevent secondary adverse effects of high
bloodglucoseontheimmunefunctionby
correcting hyperglycemia as outlined
above. Second, there may be other direct
and indirect effects of insulin on the
immunesystem.Indeed,previousstudies
have shown that insulin has strong anti-
inﬂammatory properties and suppresses
the production of a range of early proin-
ﬂammatory substances including TNF-a,
macrophage migration inhibitory factor,
superoxide anions, and intranuclear NF-
kB (17,18). In rat hepatoma cells, insulin
wasshowntodirectlyinhibitcytokine-in-
duced transcription of different acute
phase proteins (19). Another study inves-
tigated possible anti-inﬂammatory effects
of insulin in healthy subjects (17). Glu-
cose concentrations were maintained sta-
ble at baseline values with dextrose and
Table 1—Inﬂuence of diabetes/hyperglycemia on innate and adaptive immunity and other
factors
System Impaired organ/cell Main effects
Selected
references
Innate immunity
Cellular Neutrophils,
monocytes,
and macrophages
Dysfunction in adhesion,
transmigration, chemotaxis,
phagocytosis, microbial killing,
apoptosis, and capability of
antigen presentation (5–8,11)
Humoral Complement Low or high levels of several
complement components (14)
Cytokines Baseline increased levels of TNF-a,
IL-6
Impaired cellular (in vitro) cytokine
production of TNF-a, IL-1b,I L - 8 ,
IL-6, IFN-g at baseline and under
LPS stimulation (increased or
decreased) (8)
Impaired sequential patterns of
cytokine production (9)
Impaired local cytokine
production (10)
Adaptive immunity
Cellular T-cells Impaired response against different
antigens (12,13)
Humoral Immunoglobulins Quantitative defects: decrease in
amount of global and speciﬁc
antibodies (14,53)
Qualitative defects: glycosylation
of antibodies, impaired humoral
responses (13,15)
Endothelium Reduction in vasodilatation
response; inﬂammatory
endothelial activation: increased
levels of adhesion molecules
(VCAM-1, ICAM-1, E-Selectin)
(5,8,22–24,
54,55)
Coagulation Induction of a procoagulant state:
increased levels of TFP activity,
FVIIa, FVIII, thrombin-antithrombin
complexes, von Willebrand factor,
TFPI activity, and a decrease in
PAI-1 activity (7,23,56)
Miscellaneous Microbial
colonization
Increased rate of colonization by
pathogenic bacteria (nasal
Staphylococcus aureus, pharyngeal
gram negative bacteria, yeast)
Other organ
systems
Diabetic gastropathy, urinary
bladder dysfunction, reduced
bronchial reactivity, and
diminished bronchodilation
Dysfunctions presented are obtained from literature based on diabetic patient and diabetic animal models.
References regarding effect of hyperglycemia on healthy cells (in vitro) or healthy individuals (in vivo) have
not been included. ICAM, intercellular adhesion molecule; LPS, lipopolysaccharide; PAI, plasminogen ac-
tivator inhibitor;TFP, tissue factor procoagulant;TFPI,tissue factor procoagulant inhibitor; VCAM, vascular
cell adhesion molecule.
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Diabetes and sepsisinsulin infusions (clamp), and this treat-
ment was compared with saline infusions
to study the direct effects of glucose. The
investigators found a signiﬁcant downre-
gulation of intranuclear NF-kBa n dr e a c -
tiveoxygenspeciesuponinsulininfusion.
Furthermore, soluble intercellular adhe-
sion molecule-1, monocyte chemoattrac-
tant protein-1,andplasminogen activator
inhibitor-1 levelsd r o p p e ds i g n i ﬁcantly
following insulin infusion, while glucose
or saline infusions showed no alterations.
Another in vitro study found that insulin
induces a shift in T-cell differentiation to-
ward T helper type 2 cells. This resulted
in a decrease in the interferon-g–to–IL-4
ratioby33%(20).Inaddition,therewasa
signiﬁcantlyfasterdecreaseinthelevelsof
inﬂammatory mediators (i.e., C-reactive
protein, white blood count) and resolu-
tion of hyperthermia in patients treated
with high-dose intensive insulin therapy
as compared with conventional-treated
patients (21). Within this study, a multi-
variate-adjusted analysis suggested that
the anti-inﬂammatory action on overall
inﬂammation (as measured by C-reactive
protein concentrations) largely explained
the beneﬁcial effects of intensive insulin
therapy on morbidity and mortality.
Diabetes induces endothelial dysfunc-
tion and a procoagulant state. Diabetes
and sepsis are both associated with acti-
vation of the vascular endothelium. In
sepsis, activation of the endothelium oc-
curs through a cascade of inﬂammatory
mediators, which is crucial for the im-
mune response. However, widespread
excessive endothelial activation contrib-
utes to organ dysfunction as observed in
severe sepsis and septic shock. Several of
the endothelial pathways that are acti-
vated during sepsis are also found to be
upregulated in diabetic patients without
infection. Thus, for example, increased
concentrations of plasma adhesion mole-
cules (vascular cell adhesion molecule-1,
intercellular adhesion molecule-1, E-Se-
lectin) have been detected in patients and
animal models with type 1 and type 2
diabetes (22). Obesity-related increases
in proinﬂammatory cytokines induce an
inﬂammatory cascade at the level of the
endothelium in diabetic mice (23). Hy-
perglycemiaand oxidativestressareother
factors that directly activate cell adhesion
molecules, pro- and anti-inﬂammatory
molecules, and vascular endothelial
growth factor signaling in human endo-
thelial cells (24). Moreover, some studies
have linked the extent of insulin resis-
tance, as estimated with short insulin
tolerance tests, to increased levels of ad-
hesionmolecules(24).However,whether
endothelial dysfunction is exacerbated in
diabetic subjects compared with nondia-
betic subjects during sepsis remains un-
clear. Emerging evidence suggests that
insulin therapy has direct effects on the
endotheliumbeyondthecorrectionofhy-
perglycemia.Arecentstudyincludinghy-
perglycemic patients with prolonged
criticalillnessfoundthatcorrectionofhy-
perglycemia with intensive insulin ther-
apy resulted in reduced endothelial cell
activation demonstrated by a decrease in
concentrations of circulating adhesion
molecules (25). The main mechanism
identiﬁed in this study was a direct sup-
pression of the inducible nitric oxide
synthase gene expression and lower cir-
culatingnitricoxidelevelsbyinsulinther-
apy. Similarly, insulin therapy increased
arterialbloodﬂowintheforearm(asmea-
sured by strain-gauge plethysmography)
at 24 and 72 h after initiation of therapy
in diabetic patients (26).
Clinical evidence regarding infection
susceptibility and outcomes
Diabetic patients have increased sus-
ceptibility to infection. Contrary to
common belief, the association between
diabetes and increased susceptibility to
infection was not clear for a long time.
Recent clinical reports, however, provide
reasonably solid evidence that suscepti-
bility to avarietyofinfectionsisincreased
in diabetic patients (Table 2A). In addi-
tion, several unusual infections such as
malignant external otitis, rhinocerebral
mucormycosis,emphysematouspyelone-
phritis, and emphysematous cholecystitis
occur almost exclusively in diabetic pa-
tients (reviewed in [27] and [28]). Diabe-
tes-related complications such as
microvascular damage and neuropathy
are important causes of skin ulceration,
which likely predisposes patients to sec-
ondary skin infections. In a database
study using patient data from 8,655 dia-
betic patients and demographically
matched control subjects across the U.S.,
diabetes was identiﬁed as an important
risk factor for skin infections including
abscess and cellulitis (adjusted odds ratio
[OR] 2.8) (29). Other infections such as
urinary tract infections (UTIs) are also
morecommonindiabeticsubjects.Apro-
spective case-control study in 218 dia-
betic patients and 799 sex-matched
control subjects found a twofold increase
in the relative risk of UTIs in diabetic
w o m e nc o m p a r e dw i t hc o n t r o ls u b j e c t s
(30). Different potential mechanisms
contributing to the increased susceptibil-
ity for UTIs in diabetic subjects were pos-
tulated. Higher glucose concentrations in
urine may promote the growth of patho-
genic bacteria and act as a culture me-
dium. Genitourinary neurologic damage
due to diabetes may result in dysfunc-
tional bladder voiding and relative uri-
nary retention, resulting in conditions
conducive to UTI. Bacteriuria in patients
with diabetes may result in severe infec-
tions such as emphysematous pyelone-
phritis, papillary necrosis, perinephric
abscess, and candida pyelonephritis (re-
viewed in [27]).
In addition, there is evidence at a
population level for increased incidence
of infection in diabetic patients compared
with nondiabetic subjects. A large cohort
study using a Canadian database with .1
million patients found that nearly half of
all people with diabetes had at least one
hospitalization or physician claim for an
infectious disease. In comparison with
nondiabetic subjects, the risk ratio (RR)
for acquiring an infection was 1.21
(99% CI 1.20–1.22) and the RR for an
infectious disease-related hospitalization
was 2.17 (2.10–2.23) (31). The in-hospi-
talmortality inthesehospitalizedpatients
withdiabetes,however,wasnotincreased
(RR 0.95 [95% CI 0.89–1.01] and 0.94
[0.87–1.01] for the 1999 and 1996 co-
horts). A population-based longitudinal
study from Europe with 10,063 patients
also found an increased risk of infection-
related hospitalization among diabetic
subjects (32). Within this study, hyper-
glycemia carried an increased risk of in-
fection as each 1 mmol/L increase in
plasma glucose at baseline was associated
with a 6–10% increased relative risk of
pneumonia, UTI, and skin infection, after
adjustment for other possible confound-
ers. In addition, diabetic patients are at
higher risk for the spread of tuberculosis
(33) and systemic fungal infections such
as peritonitis caused by back spread from
vulvovaginal candidiasis or intracranial
manifestations due to the spread from
mucormycosis (reviewed in [27]). Diabe-
tes also was previously found to be the
singlemostimportantpredisposingfactor
in true community-acquired candidemia
(34).
Some methodological issues require
consideration.Moststudiesdidnothavea
detailed characterization of patients and
the inﬂuence of diabetes-related factors
such as type of diabetes, degree of obesity
and insulin resistance, long-term glycemic
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Schuetz, Castro, and ShapiroTable 2—Clinical studies investigating association between diabetes and susceptibility and outcome of infections
A. Studies investigating susceptibility of diabetic subjects to acquire infections
Author Year Infection type n Study design
Main outcome
measures Main ﬁndings
Zhao (29) 2009 Skin infection 8,655 Longitudinal
matched control
Incidence of skin
infections
Higher risk for skin infections
(adjusted OR 2.8)
Kornum (57) 2008 CAP 34,329 Population-based
matched control
Pneumonia-related
hospitalization
Increased risk for CAP-related
hospitalization (RR 1.26
[95% CI 1.21–1.31])
Benﬁeld (32) 2007 Infectious
diseases
10,063 Prospective Hospitalization,
28-day mortality
Higher risk for infection-related
hospitalizations and
UTI-related mortality
(HR 3.9 [95% CI 1.2–12.7]);
no difference in mortality
because of sepsis, CAP,
skin infection, and other
infections
Boyko (30) 2005 UTI 1,017 Longitudinal
matched control
Incidence of UTI Higher risk of UTI (RR 1.8
[95% CI 1.2–2.7]) and
antibiotic treatment (RR 2.3
[95% CI 1.3–3.9])
Thomsen (58) 2004 Pneumococcal
bacteremia
598 Matched control Bacteremia Higher risk for pneumococcal
pneumonia (OR 1.9
[95% CI 1.4 –2.6])
Shah (31) 2003 Infectious
diseases
513,749 Matched control Hospitalization,
mortality
Higher risk for hospitalization
(RR 2.17 [95% CI 2.10 –2.23])
and infection-related mortality
(1.92 [1.79 –2.05]); no
difference in in-hospital
mortality (1.05 [0.89–1.01]
and 0.84 [0.87–1.01])
B. Studies showing an adverse association between diabetes and outcome
Author Year Infection type n Study design
Main outcome
measures Main ﬁndings
Kornum (37) 2007 CAP 29,900 Population-based
cohort
Complications,
bacteremia,
mortality
Higher mortality rates (1.2
[95% CI 1.1–1.3]), but similar
rates of complications and
bacteremia; mortality within
patients with diabetes increased
when initial glucose levels
.14 mmol/L in multivariate
analysis (adjusted MMR
1.46 [95% CI 1.01–2.12]
compared with patients with
glucose ,6.1 mmol)
Thomsen (36) 2005 Enterobacteria
bacteremia
1,317 National registry Bacteremia,
30-day
mortality
Higher risk for bacteremia
(OR 2.9 [95% CI 2.4–3.4])
and a trend toward higher
30-day mortality (1.4 [1.0–2.0])
Fine (35) 1996 CAP 33,148 Meta-analysis 30-day
mortality
Higher risk for mortality
(OR 1.3 [95% Cl 1.1–1.5])
C. Studies showing no or a protective effect of diabetes on outcome
Author Year Infection type n Study design
Main outcome
measures Main ﬁndings
Stegenga (42) 2010 Septic shock
within the
ICU
830 Prospective study 28-day
mortality
Equal mortality rate (DM 31.4%,
non-DM 30.5%)
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Diabetes and sepsiscontrol, and/or the presence of secondary
micro- and macrovascular complications,
making the independent relationship be-
tween diabetes and susceptibility a bit
unclear. Moreover, epidemiologic studies
carry the risk of selection bias as physi-
cianscaringforpatientswithdiabetesmay
have had a lower threshold for hospital
admission,leadingtoanoverestimationof
the risk for infection and infection-related
hospitalizations.
Inﬂuence of diabetes on sepsis out-
comes. A series of studies has investigated
the inﬂuence of diabetes on outcome in
patients with infections and sepsis. How-
ever,theﬁndingsaresomewhatconﬂicting.
While some studies show harm from di-
abetes (Table 2B) (31,32,35–37), other
studies show no inﬂuence of diabetes on
mortality rate (38–42), and yet a third
group of studies show a protective effect
(Table 2C)( 4 3 –46).
Studies reporting increased mortality
rates in diabetic patients with infection.
In 1995, a large meta-analysis including a
total of 33,148 patients with community-
acquired pneumonia (CAP) found an
increased mortality rate in patients with
diabetes (summary OR 1.3 [95% Cl 1.1–
1.5]),whichwascomparabletotheriskof
male sex in this analysis (summary OR
1.3 [95% CI 1.2–1.4]) (35). However,
this analysis did not adjust for confound-
ing within the individual trials, and mis-
classiﬁcation of hyperglycemic patients
may have biased the results. Based on
the results of a large prospective study,
blood glucose level, but not diabetes,
waslaterincorporatedintothePneumonia
Severity Index, a prognostic score for
30-day mortality.
A retrospective matched case-control
study using a large database of adminis-
trative data from Canada (n = 513,749 in
each group) reported a higher risk for in-
fection-related mortality in diabetic pa-
tients (RR 1.9 [95% CI 1.8–2.1]) (31).
Higher mortality rates in diabetic patients
were also reported in several different
European studies. Thomsen et al. (36) re-
ported an increased risk for enterobacte-
rial bacteremia for diabetic patients
(adjustedOR2.9[95%CI2.4–3.4])using
data of 1,317casepatientsfromDenmark
and a trend toward adverse prognosis for
diabetic patients (adjusted OR for mortal-
ity 1.4 [95% CI 1.0–2.0]). Kornum et al.
(37) examined whether diabetes in-
creased the risk of death and complica-
tions following CAP in a population-based
cohort of 29,900 patients in Denmark.
He found adjusted 30- and 90-day mor-
tality rate ratios of 1.2 (95% CI 1.1–1.3)
and1.10(1.02–1.18)fordiabeticpatients,
with no difference in terms of pulmonary
complications or bacteremia. In addition,
high glucose levels on admission were as-
sociatedwithdeath(adjusted30-daymor-
tality rate ratio for glucose level $14
mmol/L was 1.46 ([1.01–2.12]). Impor-
tantly, after controlling for admission
glucose level,diabetes was no longer asso-
ciated with increased mortality (mortality
rate ratio of diabetic patients with blood
glucose levels of 6.1–11.0 mmol/L: 0.96
[0.69–1.35]). However, because hyper-
glycemia is such a prominent feature of
diabetes, it is conceptually difﬁcult to sep-
arate blood glucose levels from diabetes.
In addition, for other infections such as
tuberculosis, studies suggest that diabetic
Table 2—Continued
C. Studies showing no or a protective effect of diabetes on outcome
Author Year Infection type n Study design
Main outcome
measures Main ﬁndings
Vincent (41) 2010 Sepsis within
the ICU
3,147 Prospective study 28-day
mortality
Similar mortality after
adjustment for severity
of illness (HR 0.78
[95% CI 0.58–1.07])
Graham (46) 2010 Infectious diseases 1,509,890 Retrospective and
prospective
cohort
In-hospital
mortality
Lower adjusted OR for mortality
in both cohorts (0.75
[95% CI 0.74–0.76]
and 0.88 [0.79–0.98])
Michalia (59) 2009 Blood stream
infection
343 Prospective In-hospital
mortality
Similar mortality rates
(25.8 vs. 23.0%, P = 0.751)
Esper (43) 2009 Infectious diseases 12,500,000 National registry Respiratory failure,
in-hospital
mortality
Lower risk for respiratory failure
(9 vs. 14%, P , 0.05) and
mortality (18.5 vs. 20.6%,
P , 0.05)
Tsai (40) 2007 Blood stream
infection
839 Prospective 30-day mortality No difference in mortality rates
(HR 0.82 [95% CI 0.53–1.26])
McAlister (39) 2005 CAP 2,471 Prospective Mortality,
infection-related
complications
No difference in mortality, but
hyperglycemia had higher risk
for both complications and
mortality
Thomsen (45) 2004 Pneumococcal
bacteremia
628 Population-based
cohort study
30- and 90-day
mortality
Lower 30- and 90-day mortality
(11.1 vs. 16.5%, P , 0.01
and 16.0 vs. 19.5%, P , 0.01)
Kaplan (38) 2002 CAP 623,718 National registry In-hospital
mortality
No difference in mortality rates,
but hyperglycemia carried
ah i g h e rr i s kf o r
complications and mortality
Citations are in descending order of publication date. DM, diabetes; HR, hazard ratio.
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Schuetz, Castro, and Shapiropatients have a higher risk for treatment
failure and death (reviewed in [33]). Im-
portantly, due to changes in oral absorp-
tion, decreased protein binding of drugs,
and renal insufﬁciency with impaired
drug clearance, it has been speculated
that diabetes might alter the pharmacoki-
neticsofantimicrobial drugs,whichcould
leadtotreatmentfailureorresistance(33).
Studies reporting a lack of association
between diabetes and mortality. Other
trials found no inﬂuence of diabetes on
infection/sepsis outcomes (Table 2C)
(38–46). For CAP, a large cross-sectional
study of 623,718 Medicare recipients
.65 years of age with a mortality rate of
10.6% found a harmful association be-
tween crude in-hospital mortality and di-
abetes(unadjustedOR1.27[1.23–1.31]).
However, after adjusting for important
confounders, diabetes was found to be
mildly protective (adjusted OR 0.96
[0.93–0.99]) (38). The study does have
limitations in its observational nature
and that patients with diabeteswereiden-
tiﬁed from hospital records, thus exclud-
ing diabetic patients who were never
hospitalized. Similarly, a prospective Ca-
nadianstudyof2,471CAPpatientsfound
that hyperglycemia on admission was as-
sociated with a poor prognosis for both
diabetic and nondiabetic patients, but
overall a diabetes history did not predict
in-hospital mortality (39). No signiﬁcant
inﬂuence on outcomes was also reported
in a broader infectious diseasepopulation
of consecutive patients with different
types of community-acquired bacteremia
in Taiwan (adjusted hazard ratio 0.82
[95% CI 0.53–1.26]) (40). Regarding the
impact of diabetes on outcomes in higher
severities of sepsis, namely critically ill pa-
tients with severe sepsis or septic shock,
two very recent secondary analyses of pro-
spective studies reported no difference in
mortality rates (41,42).
Is diabetes protective during infection?
Some other reports suggest that diabetes
may in fact have a protective effect during
systemic infections. Postulated mecha-
nisms for this include beneﬁcial effects
ofexogenouslyadministeredinsulin,pre-
vention of acute lung injury (44), adapta-
tion to previous oxidant stress, and an
improved nutritional substrate in obese
patients with diabetes (47).
In a large epidemiological study in-
cluding 12,500,000 patients with sepsis
f r o mt h eU . S .N a t i o n a lH o s p i t a lD i s -
charge Survey, diabetic patients were
less likely to develop acute respiratory
failure (9 vs. 14%, P , 0.05) and had a
signiﬁcantlylowermortality rate(18.5 vs.
20.6%,P,0.05)(43).Thesameresearch
group reported previously from an inten-
sivecareunit(ICU)cohortofsepticshock
patients that diabetes was associated with
lower risk for acute respiratory distress
syndrome (relative risk of diabetic sub-
jects 0.53 [95% CI 0.28–0.98]) (44).
The authors speculated that perhaps a
blunted inﬂammatory response, an im-
paired neutrophil function, and altered
neutrophil-endothelial interaction in dia-
beticsubjects could protect against devel-
opment of acute respiratory distress
syndrome. A protective effect of diabetes
on outcomes of critically ill patients was
also suggested in a recent study (46) in-
cluding data from parallel retrospective
and prospective ICU patient cohorts. In
both datasets, diabetes had a signiﬁcantly
lower adjusted OR for mortality (0.75
[95% CI 0.74–0.76] and 0.88 [0.79–
0.98]). Finally, a population-based cohort
study in Denmark (45) with 598 commu-
nity-acquired pneumococcal bacteremia
patients found a trend toward lower mor-
tality rates in diabetic subjects (adjusted
mortality rate ratio 0.6 [0.3–1.2]).
The discrepancies among these differ-
ent diabetes outcome studies are possibly
the results of a variety of methodological
issues including selection bias, limited
sample size, incomplete gathering of in-
formation concerning type of diabetes,
metabolic control, secondary diabetes-
related complications (i.e., chronic renal
failure),andotherdiabetes-relatedfactors.
Unmeasured confounding may lead to
an overestimation of diabetes-related risks.
Anotherimportantconfoundingfactormay
be the change in paradigm concerning
insulin therapy for hyperglycemia in all
critically ill patients within the last decade
based on randomized-controlled trials
(48).
Inﬂuence of hyperglycemia in diabetic
and nondiabetic patients. Hyperglyce-
mia during critical illness and sepsis was
previously proposed to be a beneﬁcial,
adaptive response to provide additional
energy to organs that predominantly rely
on glucose (48). However, clinical trials
have demonstrated an association be-
tween hyperglycemia and adverse out-
comes in septic patients with a U-shaped
curve (49)—patients with low and high
glucose levels have worse outcomes com-
pared with those in the normal/moderate
range. Notably, some studies demon-
s t r a t e da na s s o c i a t i o nb e t w e e nh y p e r g l y -
cemia and increased mortality in
nondiabetic patients, but not in diabetic
patients (37,46). These ﬁndings suggest
that relatively acute hyperglycemia may
have a different pathophysiologic effect
in nondiabetic patients compared with
patients with pre-existing diabetes. How-
ever, it remains unproven whether the as-
sociation of hyperglycemia and mortality
in nondiabetic patients isentirely because
of the toxic effects of hyperglycemia or if
hyperglycemiaissimplyamarkerofstress
and severity of disease.
Inﬂuence of insulin therapy on out-
comes. To establish a causal relationship
between tight glucose control with in-
tensive insulin therapy and mortality,
randomized controlled trials were per-
formed inthe critical caresetting toassess
the impact of preventing and/or treating
hyperglycemia as compared with tolerat-
ing hyperglycemia. van den Berghe et al.
(48) published the results from a large
surgical ICU trial from Leuven, Belgium,
where a lower overall mortality rate was
found among patients treated with tight
glucose control. Speciﬁcally, the greatest
reduction in death was observed in pa-
tients with multiple-organ failure because
of a proven septicfocus. A reduced risk of
secondary infection was also found in the
insulin therapy group, with a 46% reduc-
tion in the risk of developing sepsis and a
35% reduction in the need for prolonged
(.10 days) antibiotic therapy. van den
Bergheetal.thenconductedasubsequent
trial in medical ICU patients that found a
mortality reduction only in patients trea-
ted for three or more days (50). Here, the
proportion of patients who had second-
ary bacteremia or received prolonged an-
tibiotic therapy was not signiﬁcantly
reduced. Two more recent large-scale tri-
als could not replicate the initial promis-
ing ﬁndings from Belgium and reported
higher complication rates within the tight
glucose control group (51,52). Brunk-
horst et al. (51) included 537 patients
with severe sepsis and found no differ-
ence in mortality but higher rates of
hypoglycemia in intensively treated pa-
tients. In the Normoglycemia in Intensive
Care Evaluation–Survival Using Glucose
Algorithm Regulation (NICE-SUGAR)
study, Finfer et al. (52) included 6,104
medical ICU patients from 42 centers
and reported higher mortality rates for
patients in the intensive insulin treatment
arm. Of note, patients with severe sepsis
alsotendedtodoworsewhentreatedwith
intensive insulin therapy (OR 1.13 [95%
CI 0.89–1.44]).
However, these trials differed sub-
stantially in terms of patient population,
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tantly,thelevelofglycemiccontrolwithin
the control arm: while the Leuven studies
treated control patients at the renal
threshold of 11 mmol/L, the subsequent
trials targeted an intermediate blood glu-
cose level of 8–10 mmol/L. Therefore,
there is no deﬁnite answer of whether in-
tensive glucose control has a long-term
beneﬁcial effect on the survival of septic
patients, and the effect of insulin therapy
in sepsis is not clearly delineated.
Conclusions and future directions
It is relatively clear from preclinical stud-
ies that several features associated with
diabetes inﬂuence host response to in-
fection. Hyperglycemia impacts different
components of the host response includ-
ing function of immune cells and regula-
tion of cytokines. Increased endothelial
cell activation and procoagulant changes
are found in diabetic subjects, but
whether these changes alter endothelial
function during sepsis remains unclear.
Insulin therapy seems to have protective
effects by both correcting hyperglycemia
as well as through direct effects on cells.
Clinical studies ﬁnd a higher susceptibil-
ity for diabetic patients to acquire infec-
tions.However,whetherdiabeticsubjects
with infection have a worse prognosis is
less clear. Clinical data show both ex-
tremes with some studies showing a
harmful association between diabetes
and mortality, while others show no
association or a protective effect. In addi-
tion, the role for intensive insulin treat-
mentinseverelyillsepticpatientsremains
controversial.
The interpretation of preclinical and
clinical data is challenging. Many basic
science researchers use a hyperglycemia
model where diabetes is induced in ani-
mals by destroying the pancreatic b-cells,
similar to a type 1 diabetic patient with
recent onset of disease. These models,
however, may not unconditionally apply
to type 2 diabetic patients. Other re-
searchers reproduce type 2 diabetes by
using models with leptin-deﬁcient obese
mice. These models may not accurately
account for long-term complications of
hyperglycemia such as arteriosclerosis
and chronic renal failure. The clinical
studiesareoftenhamperedbyincomplete
characterization of type and duration of
diabetes, long-term metabolic control,
degree of obesity and insulin resistance,
and secondary micro- and macrovascular
complications. It would also be interest-
ing to investigate whether genetic
polymorphisms account for differences
in susceptibility and outcomes as demon-
strated for other diseases. Moreover, pa-
tients with diabetes may have a lower
threshold for hospital admission, which
couldleadtoaselectionbiaswhenreport-
ing susceptibility rates and expected risks
and outcomes.
Future research should focus on di-
abetes as a syndrome, taking into consid-
eration important confounding factors
such as hyperglycemia, obesity, secondary
micro- and macrovascular complications,
insulin therapy, endothelial dysfunction,
and others to better understand the com-
plex interplay of diabetes and sepsis in
humans.
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